Document is current
Any future updates will be listed below
-
Authors
Asai, Kazuhisa https://orcid.org/0000-0001-8400-863X
Morioka, Yoriko
Ito, Risako https://orcid.org/0009-0006-6820-0561
Komatsubara, Masaki
Maruoka, Hiroki
-
Funding
Funding for this research was provided by:
GSK (214953)
- License Information
-
More Information
Article History
Received: 16 July 2025
Accepted: 28 October 2025
First Online: 28 November 2025
Declarations
:
: Kazuhisa Asai has received speaker/consultancy fees from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, and Sanofi. Yoriko Morioka, Risako Ito, Masaki Komatsubara, and Hiroki Maruoka are employees of, and/or hold financial equities in, GSK.
: This study was reviewed and approved by the Ethics Review Board of Kitamachi Clinic central ethics committee (approval number GSK08027) and conducted in accordance with the declaration of Helsinki and the Japanese Good Post Marketing Study Practice ordinance. All patients provided informed, written consent.
